Bayer receives first approval for Eylea ® in China (for specialized target groups only)

Eylea is the first anti-VEGF drug approved in China for the treatment of visual impairment due to diabetic macular edema in patients with DME
Source: Bayer Company News - Category: Pharmaceuticals Source Type: news